Clinical Trial Update: SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination of tazemetostat with rituximab in relapsed/refractory follicular lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Tazemetostat (tazemetostat)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-11-21